Tracey L. O’Connor

4.0k total citations
59 papers, 1.4k citations indexed

About

Tracey L. O’Connor is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Tracey L. O’Connor has authored 59 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 14 papers in Cancer Research. Recurrent topics in Tracey L. O’Connor's work include Breast Cancer Treatment Studies (14 papers), Advanced Breast Cancer Therapies (12 papers) and Cancer Treatment and Pharmacology (11 papers). Tracey L. O’Connor is often cited by papers focused on Breast Cancer Treatment Studies (14 papers), Advanced Breast Cancer Therapies (12 papers) and Cancer Treatment and Pharmacology (11 papers). Tracey L. O’Connor collaborates with scholars based in United States, United Kingdom and Nigeria. Tracey L. O’Connor's co-authors include Stephen B. Edge, Ellis Levine, Foluso O. Ademuyiwa, Christine B. Ambrosone, Adrienne Groman, Nuttapong Ngamphaiboon, Charles L. Loprinzi, Andrew L. Himelstein, John D. Roberts and Stephen S. Grubbs and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Tracey L. O’Connor

54 papers receiving 1.3k citations

Peers

Countries citing papers authored by Tracey L. O’Connor

Since Specialization

Citations

This map shows the geographic impact of Tracey L. O’Connor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tracey L. O’Connor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tracey L. O’Connor more than expected).

Fields of papers citing papers by Tracey L. O’Connor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tracey L. O’Connor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tracey L. O’Connor. The network helps show where Tracey L. O’Connor may publish in the future.

Co-authorship network of co-authors of Tracey L. O’Connor

This figure shows the co-authorship network connecting the top 25 collaborators of Tracey L. O’Connor. A scholar is included among the top collaborators of Tracey L. O’Connor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tracey L. O’Connor. Tracey L. O’Connor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Feasibility, Acceptability, and Outcomes of Project Rally: Pilot Study of a YMCA-Based Pickleball Program for Cancer Survivors 2025 ·Healthcare ·Nathan H. Parker, (unknown), (unknown), Kea Turner, Steven K. Sutton, Tracey L. O’Connor, Jeffrey Huang, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Susan T. Vadaparampil, Jennifer Irvin Vidrine	0
2	Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer 2025 ·Oncogene ·Agnieszka K. Witkiewicz, (unknown), Emily Schultz, (unknown), Tracey L. O’Connor, Ellis Levine, Erik S. Knudsen	0
3	Abstract PO1-18-03: Chemokine-modulating regimen (rintatolimod, IFN-α2b, celecoxib): New strategy to drive CD8+T-cells into triple negative breast cancer 2024 ·Cancer Research ·Shipra Gandhi, (unknown), Mateusz Opyrchal, (unknown), Kristopher Attwood, Jianmin Wang, Eduardo Cortes Gomez, Tracey L. O’Connor, Ellis Levine, Paweł Kaliński	1
4	Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study 2024 ·Journal of Cancer Survivorship ·Mina S. Sedrak, Can‐Lan Sun, (unknown), Rachel A. Freedman, Allison Magnuson, Tracey L. O’Connor, Beverly Moy, Tanya M. Wildes, Heidi D. Klepin, Andrew E. Chapman, William P. Tew, Efrat Dotan, Mary Anne Fenton, Heeyoung Kim, Vani Katheria, Hyman B. Muss, Harvey Jay Cohen, Cary P. Gross, Jingran Ji	5
5	Palbociclib in adults aged 70 years and older with advanced breast cancer: A phase 2 multicenter trial (Alliance A171601) 2024 ·Journal of Geriatric Oncology ·Mina S. Sedrak, Minji K. Lee, Jingran Ji, Daniel Satele, Rachel A. Freedman, Philip D. Poorvu, Tracey L. O’Connor, Grant R. Williams, Judith O. Hopkins, Hyman B. Muss, Harvey Jay Cohen, Ann H. Partridge, Lisa A. Carey, (unknown), (unknown), Jennifer Le‐Rademacher, Aminah Jatoi	4
6	Phase I/II study of stereotactic radiation and sacituzumab govitecan with zimberelimab in the management of metastatic triple negative breast cancer with brain metastases. 2024 ·Journal of Clinical Oncology ·Kamran A. Ahmed, Youngchul Kim, (unknown), Daniel Oliver, Matthew N. Mills, (unknown), (unknown), Ricardo Costa, Kimberley Lee, Loretta Loftus, Tracey L. O’Connor, Hatem Soliman, (unknown), Michael A. Vogelbaum, Peter Forsyth, John A. Arrington, Marilin Rosa, Michael Yu, Hyo S. Han	0
7	Falls prechemotherapy and toxicity‐related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial 2023 ·Cancer ·Jingran Ji, (unknown), Can‐Lan Sun, Tanya M. Wildes, Rachel A. Freedman, Allison Magnuson, Tracey L. O’Connor, Beverly Moy, Heidi D. Klepin, Andrew E. Chapman, William P. Tew, Efrat Dotan, Mary Anne Fenton, Heeyoung Kim, Vani Katheria, Cary P. Gross, Harvey Jay Cohen, Hyman B. Muss, Mina S. Sedrak	6
8	Determinants of response to CDK4/6 inhibitors in the real-world setting 2023 ·npj Precision Oncology ·Agnieszka K. Witkiewicz, Emily Schultz, Jianxin Wang, (unknown), Ellis Levine, Tracey L. O’Connor, Erik S. Knudsen	16
9	Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx 2023 ·Journal for ImmunoTherapy of Cancer ·Shipra Gandhi, Mateusz Opyrchal, Melissa Grimm, (unknown), Kathleen M. Kokolus, Agnieszka K. Witkiewicz, Kristopher Attwood, Adrienne Groman, Lauren Williams, (unknown), Paul K. Wallace, (unknown), Hans Minderman, Orla Maguire, Tracey L. O’Connor, Amy Early, Ellis Levine, Paweł Kaliński	10
10	Associations between Serum 25-Hydroxyvitamin D Levels and Health-Related Quality-of-Life Measures in Patients with Breast Cancer: A Longitudinal Study 2022 ·Cancer Epidemiology Biomarkers & Prevention ·(unknown), (unknown), Kristopher Attwood, Yali Zhang, Tracey L. O’Connor, (unknown), (unknown), Christine B. Ambrosone, Song Yao, Chi‐Chen Hong	1
11	Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center 2022 ·The Oncologist ·Erik S. Knudsen, Emily Schultz, (unknown), Kristopher Attwood, Stephen B. Edge, Tracey L. O’Connor, Ellis Levine, Agnieszka K. Witkiewicz	20
12	Recruitment and Retention of Healthy, Postmenopausal Women of African and European Ancestry: Results from a Dietary Intervention with Repeated Biospecimen Collections 2022 ·Current Developments in Nutrition ·Susan E. McCann, Elisa M. Rodriguez, Deborah O. Erwin, Song Yao, David Tritchler, Meredith A.J. Hullar, Tracey L. O’Connor, Johanna W. Lampe	1
13	Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer 2021 ·Journal of Clinical Oncology ·Allison Magnuson, Mina S. Sedrak, Cary P. Gross, William P. Tew, Heidi D. Klepin, Tanya M. Wildes, Hyman B. Muss, Efrat Dotan, Rachel A. Freedman, Tracey L. O’Connor, William Dale, Harvey Jay Cohen, Vani Katheria, (unknown), Abrahm Levi, Heeyoung Kim, Supriya G. Mohile, Arti Hurria, Can-Lan Sun	76
14	Cancer During Pregnancy: The Oncologist Overview 2019 ·World Journal of Oncology ·Adriana Hepner, (unknown), (unknown), Pedro Exman, Laura Testa, (unknown), José Roberto Filassi, Rossana Pulcineli Vieira Francisco, Marcelo Zugaib, Tracey L. O’Connor, Michael G. Martin	77
15	Osteonecrosis of The Jaw: Dental Outcomes in Metastatic Breast Cancer Patients Treated With Bisphosphonates With/Without Bevacizumab 2011 ·Clinical Breast Cancer ·Nuttapong Ngamphaiboon, Jennifer Frustino, (unknown), Maureen Sullivan, Tracey L. O’Connor	26
16	Impact of body mass index on clinical outcomes in triple‐negative breast cancer 2011 ·Cancer ·Foluso O. Ademuyiwa, Adrienne Groman, Tracey L. O’Connor, Christine B. Ambrosone, Nancy Watroba, Stephen B. Edge	87
17	Pretreatment Serum Concentrations of 25-Hydroxyvitamin D and Breast Cancer Prognostic Characteristics: A Case-Control and a Case-Series Study 2011 ·PLoS ONE ·Song Yao, Lara E. Sucheston, Amy E. Millen, Candace S. Johnson, Donald L. Trump, Mary Nesline, Warren Davis, Chi-Chen Hong, Susan E. McCann, Helena Hwang, Swati Kulkarni, Stephen B. Edge, Tracey L. O’Connor, Christine B. Ambrosone	88
18	Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis 2011 ·Medical Oncology ·Nuttapong Ngamphaiboon, Tracey L. O’Connor, Pooja Advani, Ellis Levine, (unknown)	17
19	Cancer-Related Fatigue 2010 ·Journal of the National Comprehensive Cancer Network ·Ann M. Berger, Amy Pickar Abernethy, (unknown), Andrea M. Barsevick, William Breitbart, David Cella, Bernadine Cimprich, Charles S. Cleeland, Mario A. Eisenberger, Carmen P. Escalante, Paul B. Jacobsen, (unknown), Jennifer A. Ligibel, Barbara A. Murphy, Tracey L. O’Connor, William F. Pirl, Eve T. Rodler, Hope S. Rugo, James Thomas, Lynne I. Wagner	216
20	An Unusual Cause of Cholecystitis? 2005 ·American Journal of Clinical Oncology ·(unknown), Joseph Geradts, Tracey L. O’Connor	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact